This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n9http://linked.opendata.cz/resource/domain/vavai/projekt/
n15http://linked.opendata.cz/resource/domain/vavai/subjekt/
n14http://linked.opendata.cz/ontology/domain/vavai/
n4http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n6http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064173%3A_____%2F13%3A%230000375%21RIV14-MZ0-00064173/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064173%3A_____%2F13%3A%230000375%21RIV14-MZ0-00064173
rdf:type
skos:Concept n14:Vysledek
dcterms:description
We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually. We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually.
dcterms:title
10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group
skos:prefLabel
10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group
skos:notation
RIV/00064173:_____/13:#0000375!RIV14-MZ0-00064173
n14:predkladatel
n15:ico%3A00064173
n3:aktivita
n12:V n12:Z n12:P
n3:aktivity
P(NT12215), P(NT14393), V, Z(MSM0021622434)
n3:cisloPeriodika
9
n3:dodaniDat
n7:2014
n3:domaciTvurceVysledku
n20:6344747
n3:druhVysledku
n16:J
n3:duvernostUdaju
n11:S
n3:entitaPredkladatele
n19:predkladatel
n3:idSjednocenehoVysledku
119603
n3:idVysledku
RIV/00064173:_____/13:#0000375
n3:jazykVysledku
n18:eng
n3:klicovaSlova
Multiple myeloma; Thalidomide
n3:klicoveSlovo
n10:Multiple%20myeloma n10:Thalidomide
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[847083980703]
n3:nazevZdroje
Leukemia Research
n3:obor
n13:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
22
n3:projekt
n9:NT12215 n9:NT14393
n3:rokUplatneniVysledku
n7:2013
n3:svazekPeriodika
37
n3:tvurceVysledku
Gregora, Evžen
n3:wos
000324097600014
n3:zamer
n4:MSM0021622434
s:issn
0145-2126
s:numberOfPages
7
n6:doi
10.1016/j.leukres.2013.06.019